Evolus, Inc. (EOLS) 8-K Current Report: March 13, 2026
Filed: March 13, 2026
Health Care
Pharmaceutical PreparationsEvolus, Inc. (EOLS) 8-K current report filed with SEC EDGAR on March 13, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 5.02: Departure/Election of Directors or Officers
Evolus, Inc. 8-K Mar 13, 2026 Event Analysis
Item 5.02 · Departure/Election of Directors or Officers
- • Vikram Malik reclassified from Class III to Class II director on March 13, 2026 to rebalance Evolus's classified board after Simone Blank's departure
- • Malik retains Chairman of the Board and Compensation Committee roles — no change in influence or oversight function
- • Malik's term now runs only to the 2026 annual meeting, when he must stand for stockholder election as a Class II director
- • No new equity awarded; existing grants vest on original schedule — no incremental dilution from this restructuring
- • Board now evenly split: 6 directors, 2 per class — governance structure restored to intended design
Other Evolus, Inc. 8-K Filings
Get deeper insights on Evolus, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.